454
views
views
The recommendation for the scientific research of low-dose naltrexone (LDN) to treat multiple sclerosis (MS) was initially presented as a medical theory in 2005. Shortly after, an open-label multi-centered pilot trial including 40 patients evaluated the tolerability and safety of LDN in the initial progression of MS...
Clinical significance of low dose naltrexone in treating Multiple Sclerosis
The recommendation for the scientific research of low-dose naltrexone (LDN) to treat multiple sclerosis (MS) was initially presented as a medical theory in 2005. Shortly after, an open-label multi-centered pilot trial including 40 patients evaluated the tolerability and safety of LDN in the initial progression of MS...